|
Condensed Consolidated Financial Statement Detail (Details)
|
3 Months Ended | 6 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2012
USD ($)
|
Jun. 30, 2011
|
Jun. 30, 2012
USD ($)
|
Jun. 30, 2011
|
Dec. 31, 2011
USD ($)
|
Jun. 30, 2012
Five year warrants issued in February 2010 [Member]
USD ($)
|
Dec. 31, 2011
Five year warrants issued in February 2010 [Member]
USD ($)
|
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
USD ($)
|
Jun. 30, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Jun. 30, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Mar. 01, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Jun. 30, 2012
Warrants issued to private investors [Member]
USD ($)
|
Dec. 31, 2011
Warrants issued to private investors [Member]
USD ($)
|
Jun. 30, 2010
Warrants issued to private investors [Member]
|
Jun. 30, 2009
Warrants issued to private investors [Member]
USD ($)
|
Jun. 30, 2012
Options Contract [Member]
USD ($)
|
Jun. 30, 2012
Options Contract [Member]
USD ($)
|
Jun. 30, 2012
Options Contract [Member]
EUR (€)
|
Jan. 31, 2016
Options Contract [Member]
EUR (€)
|
Jan. 31, 2014
Options Contract [Member]
EUR (€)
|
Jun. 30, 2012
Common stock options and restricted stock units [Member]
|
Jun. 30, 2011
Common stock options and restricted stock units [Member]
|
Jun. 30, 2012
Common stock options and restricted stock units [Member]
|
Jun. 30, 2011
Common stock options and restricted stock units [Member]
|
Jun. 30, 2012
Convertible preferred stock [Member]
|
Jun. 30, 2011
Convertible preferred stock [Member]
|
Jun. 30, 2012
Convertible preferred stock [Member]
|
Jun. 30, 2011
Convertible preferred stock [Member]
|
Jun. 30, 2012
Warrants for common stock [Member]
|
Jun. 30, 2011
Warrants for common stock [Member]
|
Jun. 30, 2012
Warrants for common stock [Member]
|
Jun. 30, 2011
Warrants for common stock [Member]
|
||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||||||||||||||||||||||||||||||||
| Antidilutive securities excluded from computation of earnings per share (in shares) | 21,823,000 | 5,457,000 | 16,645,000 | 5,453,000 | 5,121,000 | 3,833,000 | 5,566,000 | 3,711,000 | 0 | 17,000 | 0 | 135,000 | 16,702,000 | 1,607,000 | 11,079,000 | 1,607,000 | ||||||||||||||||||||
| Cash and cash equivalents [Abstract] | ||||||||||||||||||||||||||||||||||||
| Demand deposit | $ 9,900,000 | $ 9,900,000 | $ 21,100,000 | |||||||||||||||||||||||||||||||||
| Money market funds | 30,000,000 | 30,000,000 | 27,200,000 | |||||||||||||||||||||||||||||||||
| U.S. treasury securities | 15,000,000 | 15,000,000 | ||||||||||||||||||||||||||||||||||
| Short-term Investments [Abstract] | ||||||||||||||||||||||||||||||||||||
| Short-term investments, U.S. treasury securities | 11,993,000 | 11,993,000 | 0 | |||||||||||||||||||||||||||||||||
| Derivative [Line Items] | ||||||||||||||||||||||||||||||||||||
| Derivative, amount of hedged item | 15,000,000 | 1,500,000 | ||||||||||||||||||||||||||||||||||
| Number of foreign exchange option contracts | 2 | 2 | 2 | |||||||||||||||||||||||||||||||||
| Derivative, premiums | 1,500,000 | |||||||||||||||||||||||||||||||||||
| Derivative fair value | 600,000 | 600,000 | ||||||||||||||||||||||||||||||||||
| Derivative, loss | 300,000 | 600,000 | ||||||||||||||||||||||||||||||||||
| Debt and accrued interest payments in Euros | 15,000,000 | |||||||||||||||||||||||||||||||||||
| Accrued liabilities [Abstract] | ||||||||||||||||||||||||||||||||||||
| Accrued payroll and other benefits | 2,306,000 | 2,306,000 | 3,007,000 | |||||||||||||||||||||||||||||||||
| Accrued management incentive compensation | 1,894,000 | 1,894,000 | 4,096,000 | |||||||||||||||||||||||||||||||||
| Accrued clinical trial costs | 1,927,000 | 1,927,000 | 140,000 | |||||||||||||||||||||||||||||||||
| Accrued severance payments | 403,000 | 403,000 | 1,207,000 | |||||||||||||||||||||||||||||||||
| Other | 1,336,000 | 1,336,000 | 1,562,000 | |||||||||||||||||||||||||||||||||
| Total | 7,866,000 | 7,866,000 | 10,012,000 | [1] | ||||||||||||||||||||||||||||||||
| Class of Warrant or Right [Line Items] | ||||||||||||||||||||||||||||||||||||
| Warrants outstanding (in shares) | 1,260,000 | 14,829,167 | 14,834,577 | 347,826 | ||||||||||||||||||||||||||||||||
| Exercise price (in dollars per share) | $ 1.76 | $ 1.76 | $ 10.5 | $ 1.76 | $ 19.5 | |||||||||||||||||||||||||||||||
| Fair value of warrant liability | 300,000 | 23,300,000 | 23,300,000 | 6,400,000 | 100,000 | |||||||||||||||||||||||||||||||
| Gain (loss) on revaluation of warrant liability | $ 300,000 | $ (2,200,000) | $ (16,900,000) | $ 100,000 | ||||||||||||||||||||||||||||||||
| Warrants outstanding (in shares) | 14,834,577 | 14,834,577 | 1,260,000 | 14,834,577 | 347,826 | |||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||